Radiotherapy costs vary among Medicare patients with breast, lung, prostate cancers
the ONA take:
Cost of radiotherapy among Medicare patients varied most widely because of year of diagnosis, location of treatment, clinic type, and individual radiation provider, rather than factors related to a patient or that patient's cancer, according to a study published in the Journal of Oncology Practice.
These factors accounted for 44% to 61% of the variation in radiation therapy cost for patients with breast, lung, and prostate cancer, while factors associated with the patient or person's cancer accounted for less than 3% of the cost variation.
"We found that variability in Medicare reimbursement for radiotherapy does not depend on individual characteristics of patients or their cancers," said James Murphy, MD, assistant professor at UC San Diego School of Medicine and radiation therapist at Moores Cancer Center at UC San Diego Health. "Rather, reimbursement was tied to the provider, geography and technology used to treat patients. This strongly suggests inefficiency within the current Medicare reimbursement framework for radiation therapy."
The authors note that they did not evaluate whether higher radiation therapy cost was associated with higher quality radiation or improved outcomes.
Cost of radiotherapy among Medicare patients varied most widely because of year of diagnosis, location of treatment, clinic type, and provider.
- Compound in Teas, Peas, Soybeans May Increases Prostate Cancer Risk
- Fertility Preservation in Male Adolescents and Young Adults With Cancer
- Acupuncture an Effective Alternative Treatment for Cancer-Related Fatigue
- Social, Psychiatric Variables Reduce Cognitive Functioning, QoL in HNC
- Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma
- HPV and Cancer (Fact Sheet)
- Pain Control More Easily Achieved With Nurse-Led Education in Bone Metastases
- Using Nutrition-Based Strategies to Manage Adverse Effects of Cancer
- Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer
- A Case of Immunotherapy-Induced Myocarditis Concomitant to MG in Lung Cancer
- Duloxetine May Improve AI-Associated Joint Pain in Early Stage Breast Cancer
- Axillary Lymph Node Dissection Predictive for Lymphedema in Breast Cancer
- Vitamin D Supplementation is Recommended for Pediatric Patients With Sarcoma
- Extended Adjuvant Therapy for Breast Cancer Improves 5-Year Disease-free Survival
- A Structured Group Exercise Program for Patients With Metastatic Cancer Receiving Chemotherapy and CTNNB1 (β-catenin) as a Biomarker of Exercise Efficacy
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|